Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population
Amgen (NASDAQ: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists, and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes, as well as emerging antibiotic resistance in chemotherapy patients.
To help raise awareness of the risks and impact of infections in cancer patients, Amgen is joining forces with the Centers for Disease Control (CDC) Foundation, and the Divisions of Healthcare Quality and Promotion and Cancer Prevention and Control at CDC on a three-year initiative to provide resources and educational tools to help cancer patients, their caregivers and healthcare professionals.
